AR101185A1 - Anticuerpos anti-factor v o factor v activado - Google Patents

Anticuerpos anti-factor v o factor v activado

Info

Publication number
AR101185A1
AR101185A1 ARP150102212A ARP150102212A AR101185A1 AR 101185 A1 AR101185 A1 AR 101185A1 AR P150102212 A ARP150102212 A AR P150102212A AR P150102212 A ARP150102212 A AR P150102212A AR 101185 A1 AR101185 A1 AR 101185A1
Authority
AR
Argentina
Prior art keywords
seq
factor
fva
variable regions
activated antibodies
Prior art date
Application number
ARP150102212A
Other languages
English (en)
Spanish (es)
Original Assignee
Novo Nordiks As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordiks As filed Critical Novo Nordiks As
Publication of AR101185A1 publication Critical patent/AR101185A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP150102212A 2014-07-11 2015-07-10 Anticuerpos anti-factor v o factor v activado AR101185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14176717 2014-07-11

Publications (1)

Publication Number Publication Date
AR101185A1 true AR101185A1 (es) 2016-11-30

Family

ID=51162604

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102212A AR101185A1 (es) 2014-07-11 2015-07-10 Anticuerpos anti-factor v o factor v activado

Country Status (3)

Country Link
AR (1) AR101185A1 (fr)
TW (1) TW201617371A (fr)
WO (1) WO2016005564A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071116A1 (fr) * 2017-10-05 2019-04-11 Epivax, Inc. Épitopes de lymphocytes t régulateurs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2090001T3 (es) * 1994-02-14 1998-08-01 Univ Leiden Un metodo para seleccionar por la presencia de un defecto genetico asociado con trombosis y/o una pobre respuesta anticoagulante a la proteina c activada.
US20060014934A1 (en) * 2004-05-18 2006-01-19 Everse Stephen J Crystal structure of factor Vai and method for identifying blood factor Va modulators
JP2009528293A (ja) * 2006-02-23 2009-08-06 ザ チルドレンズ ホスピタル オブ フィラデルフィア 様々な形態の活性型第ｖ因子を用いた止血を調節する組成物及び方法
EP2091564A4 (fr) * 2006-10-16 2010-09-01 Novelmed Therapeutics Inc Procede d'inhibition de la coagulation avec des anticorps anti-facteur va humains et utilisation de ceux-ci

Also Published As

Publication number Publication date
WO2016005564A2 (fr) 2016-01-14
WO2016005564A3 (fr) 2016-04-07
TW201617371A (zh) 2016-05-16

Similar Documents

Publication Publication Date Title
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
PH12021550023A1 (en) Humanized anti-tau antibodies
MX2020006213A (es) Anticuerpos anti-trem2 y metodos relacionados.
PE20190737A1 (es) Anticuerpos anti-cd27
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
MX2017002230A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
CO2019013669A2 (es) Anticuerpos anti-garp-tgf-β
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MX353278B (es) Raton con cadena ligera comun.
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
CR20190009A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso.
AR105267A1 (es) Anticuerpos de unión a tau
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
AR108717A1 (es) Anticuerpos antifactor de la coagulación xi
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
MX390188B (es) Anticuerpo anti-tie 2 humano novedoso.
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EA201890340A1 (ru) Моноклональное антитело-ингибитор фактора xiia
MX386543B (es) Anticuerpo de anti-esclerostina, fragmento de unión a antigeno y uso médico del mismo.
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure